Mark C. McKenna's Trading History
| APGEApogee Therapeutics | Sep 03, 2026 | ― | Uninformative Sell | ― | $0.00 | |
| FRNMFreenome Inc | Jul 22, 2026 | Former Director | Uninformative Buy | ― | $374.40K | |
| NAMSNewAmsterdam Pharma Company | Jan 09, 2026 | Director | Uninformative Buy | ― | $207.82K | |
| BBOTBridgeBio Oncology Therapeutics | Aug 11, 2025 | Former Director | Uninformative Buy | 301.80K | $78.60K | |
| RXDXPrometheus Biosciences | Jun 16, 2023 | ― | Uninformative Sell | ― | $0.00 | |
| BHCBausch Health Companies | Aug 21, 2019 | President, Salix | Informative Sell | 235.17K | $170.20K | |
| SYRESpyre Therapeutics | ― | Director | ― | ― |
You May Also Like
Mark C. McKenna insider profile FAQ
What is the percentage of profitable transactions made by Mark C. McKenna?
The percentage of profitable transactions made by Mark C. McKenna is 100%.
What is the average return per transaction made by Mark C. McKenna?
The average return per transaction made by Mark C. McKenna is 42.50%.
What stocks does Mark C. McKenna hold?
Mark C. McKenna holds: FRNM, BHC, SYRE, NAMS, RXDX, APGE, BBOT stocks.
What was Mark C. McKenna's most profitable transaction?
Mark C. McKenna’s most profitable transaction was an Informative Buy of APGE stock on December 16, 2024. The return on the trade was 58.30%.
What is Mark C. McKenna's role in Freenome Inc?
Mark C. McKenna's role in Freenome Inc is Former Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.